Molly Henderson's Insider Trades & SAST Disclosures
Molly Henderson's most recent trade in Phathom Pharmaceuticals Inc was a trade of 72,000 Common Stock done . Disclosure was reported to the exchange on Feb. 27, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Molly Henderson.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Phathom Pharmaceuticals Inc | Molly Henderson | CFO and CBO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Feb 2025 | 72,000 | 165,546 (0%) | 0% | 0 | Common Stock | |
| Phathom Pharmaceuticals Inc | Molly Henderson | CFO and CBO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Feb 2025 | 50,000 | 50,000 | - | - | Stock Option (Right to Buy) | |
| Phathom Pharmaceuticals Inc | Molly Henderson | CFO and CBO | Sale of securities on an exchange or to another person at price $ 6.59 per share. | 21 Jan 2025 | 6,583 | 93,546 (0%) | 0% | 6.6 | 43,371 | Common Stock |
| Phathom Pharmaceuticals Inc | Molly Henderson | CFO and CBO | Sale of securities on an exchange or to another person at price $ 8.00 per share. | 19 Dec 2024 | 1,291 | 98,156 (0%) | 0% | 8 | 10,328 | Common Stock |
| Phathom Pharmaceuticals Inc | Molly Henderson | CFO and CBO | Sale of securities on an exchange or to another person at price $ 11.72 per share. | 15 Jul 2024 | 4,325 | 99,447 (0%) | 0% | 11.7 | 50,689 | Common Stock |
| Phathom Pharmaceuticals Inc | Molly Henderson | CFO and CBO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 May 2024 | 7,500 | 102,763 (0%) | 0% | 0 | Common Stoock | |
| Phathom Pharmaceuticals Inc | Molly Henderson | CFO and CBO | Sale of securities on an exchange or to another person at price $ 11.10 per share. | 08 Apr 2024 | 3,435 | 95,263 (0%) | 0% | 11.1 | 38,129 | Common Stoock |
| Phathom Pharmaceuticals Inc | Henderson Molly | CFO and CBO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jan 2024 | 120,000 | 120,000 | - | - | Stock Option (Right to Buy) | |
| Phathom Pharmaceuticals Inc | Molly Henderson | CFO and CBO | Sale of securities on an exchange or to another person at price $ 7.75 per share. | 18 Jan 2024 | 6,307 | 98,698 (0%) | 0% | 7.8 | 48,900 | Common Stock |
| Phathom Pharmaceuticals Inc | Molly Henderson | CFO and CBO | Grant, award, or other acquisition of securities at price $ 1.00 per share. | 14 Jul 2023 | 25,000 | 95,180 (0%) | 0% | 1 | 25,000 | Common Stock |
| Phathom Pharmaceuticals Inc | Molly Henderson | CFO and CBO | Sale of securities on an exchange or to another person at price $ 11.41 per share. | 02 Jun 2023 | 1,960 | 68,506 (0%) | 0% | 11.4 | 22,368 | Common Stock |
| Phathom Pharmaceuticals Inc | Molly Henderson | CFO and CBO | Sale of securities on an exchange or to another person at price $ 12.87 per share. | 22 May 2023 | 2,110 | 70,466 (0%) | 0% | 12.9 | 27,165 | Common Stock |
| Phathom Pharmaceuticals Inc | Molly Henderson | CFO and CBO | Sale of securities on an exchange or to another person at price $ 7.27 per share. | 06 Apr 2023 | 3,439 | 72,576 (0%) | 0% | 7.3 | 25,002 | Common Stock |
| Phathom Pharmaceuticals Inc | Molly Henderson | CFO and CBO | Sale of securities on an exchange or to another person at price $ 8.53 per share. | 01 Mar 2023 | 2,032 | 76,015 (0%) | 0% | 8.5 | 17,335 | Common Stock |
| Phathom Pharmaceuticals Inc | Molly Henderson | CFO and CBO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Jan 2023 | 55,000 | 55,000 | - | - | Stock Option (Right to Buy) | |
| Phathom Pharmaceuticals Inc | Molly Henderson | CFO and CBO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Jan 2023 | 33,000 | 78,047 (0%) | 0% | 0 | Common Stock | |
| Phathom Pharmaceuticals Inc | Molly Henderson | CFO and CBO | Sale of securities on an exchange or to another person at price $ 9.60 per share. | 21 Nov 2022 | 2,159 | 43,341 (0%) | 0% | 9.6 | 20,726 | Common Stock |
| Phathom Pharmaceuticals Inc | Molly Henderson | CFO and CBO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Sep 2022 | 7,500 | 45,500 (0%) | 0% | 0 | Common Stock | |
| Phathom Pharmaceuticals Inc | Molly Henderson | CFO and CBO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 May 2022 | 12,000 | 38,000 (0%) | 0% | 0 | Common Stock | |
| Phathom Pharmaceuticals Inc | Molly Henderson | CFO and CBO | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 13 May 2022 | 6,000 | 26,000 (0%) | 0% | - | Common Stock | |
| Phathom Pharmaceuticals Inc | Molly Henderson | CFO and CBO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Apr 2022 | 100,000 | 100,000 | - | - | Stock Option (Right to Buy) | |
| Phathom Pharmaceuticals Inc | Molly Henderson | CFO and CBO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Apr 2022 | 20,000 | 20,000 (0%) | 0% | 0 | Common Stock | |
| UroGen Pharma Ltd | Molly Henderson | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2022 | 30,000 | 30,000 | - | - | Stock Option (right to buy) | |
| UroGen Pharma Ltd | Molly Henderson | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2022 | 7,500 | 7,500 | - | - | Restricted Stock Units | |
| UroGen Pharma Ltd | Molly Henderson | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Jan 2022 | 666 | 5,579 (0%) | 0% | - | Ordinary Shares | |
| UroGen Pharma Ltd | Molly Henderson | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Jan 2022 | 666 | 1,334 | - | - | Restricted Stock Units | |
| UroGen Pharma Ltd | Molly Henderson | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 7.58 per share. | 31 Jan 2022 | 331 | 5,248 (0%) | 0% | 7.6 | 2,509 | Ordinary Shares |
| UroGen Pharma Ltd | Molly Henderson | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Nov 2021 | 5,000 | 10,000 | - | - | Restricted Stock Units | |
| UroGen Pharma Ltd | Molly Henderson | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Nov 2021 | 5,000 | 7,500 (0%) | 0% | - | Ordinary Shares | |
| UroGen Pharma Ltd | Molly Henderson | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 12.03 per share. | 30 Nov 2021 | 2,587 | 4,913 (0%) | 0% | 12.0 | 31,122 | Ordinary Shares |
| UroGen Pharma Ltd | Molly Henderson | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jun 2021 | 15,000 | 15,000 | - | - | Stock Option (right to buy) | |
| UroGen Pharma Ltd | Molly Henderson | Chief Financial Officer | Purchase of securities on an exchange or from another person at price $ 15.85 per share. | 17 May 2021 | 2,500 | 2,500 (0%) | 0% | 15.9 | 39,625 | Common Stock |
| UroGen Pharma Ltd | Molly Henderson | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2021 | 6,000 | 6,000 | - | - | Stock Option (right to buy) | |
| UroGen Pharma Ltd | Molly Henderson | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2021 | 2,000 | 2,000 | - | - | Restricted Stock Units |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges